Paul Ridker

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA
    Trans Am Clin Climatol Assoc 124:174-90. 2013
  2. pmc Reproductive aging-associated common genetic variants and the risk of breast cancer
    Chunyan He
    Department of Public Health, Indiana University School of Medicine, 980 West Walnut Street, R3 C241, Indianapolis, IN 46202, USA
    Breast Cancer Res 14:R54. 2012
  3. doi request reprint Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial
    Paul M Ridker
    MPH, Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Ave East, Boston, MA 02215 1204, USA
    Circulation 126:2739-48. 2012
  4. pmc Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
    Paul M Ridker
    Center for Cardiovascular Disease Prevention and the Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Curr Atheroscler Rep 15:295. 2013
  5. pmc Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Lancet 380:565-71. 2012
  6. pmc Cardiovascular inflammation in healthy women: multilevel associations with state-level prosperity, productivity and income inequality
    CHERYL R CLARK
    Division of General Medicine and Primary Care, Brigham and Women s Faulkner Hospitalist Program, Harvard Medical School, Boston, Massachusetts, USA
    BMC Public Health 12:211. 2012
  7. doi request reprint Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, MA 02215, USA
    Clin Chem 58:877-86. 2012
  8. pmc An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation
    Christopher S Coffey
    Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL 35294 0022, USA
    BMC Bioinformatics 5:49. 2004
  9. ncbi request reprint Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    J Am Coll Cardiol 45:1644-8. 2005
  10. ncbi request reprint Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women
    Paul M Ridker
    Donald W Reynolds Center for Cardiovascular Research, LeDucq Center for Molecular and Genetic Epidemiology, Brigham and Women s Hospital, Boston, MA 02215, USA
    JAMA 294:326-33. 2005

Collaborators

Detail Information

Publications154 found, 100 shown here

  1. pmc Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA
    Trans Am Clin Climatol Assoc 124:174-90. 2013
    ..Together, CIRT and CANTOS will enroll more than 25,000 patients worldwide and provide a fundamental test of the inflammatory hypothesis of atherothrombosis. ..
  2. pmc Reproductive aging-associated common genetic variants and the risk of breast cancer
    Chunyan He
    Department of Public Health, Indiana University School of Medicine, 980 West Walnut Street, R3 C241, Indianapolis, IN 46202, USA
    Breast Cancer Res 14:R54. 2012
    ..Recent genome-wide association studies have identified several novel genetic loci associated with these two traits. However, the association between these loci and breast cancer risk is unknown...
  3. doi request reprint Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial
    Paul M Ridker
    MPH, Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Ave East, Boston, MA 02215 1204, USA
    Circulation 126:2739-48. 2012
    ....
  4. pmc Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?
    Paul M Ridker
    Center for Cardiovascular Disease Prevention and the Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Curr Atheroscler Rep 15:295. 2013
    ..Together, CANTOS and CIRT represent a core test of the inflammation hypothesis of atherothrombosis and the exploration of a potential new phase for cardiovascular therapeutics...
  5. pmc Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Lancet 380:565-71. 2012
    ..We undertook an analysis of participants from the JUPITER trial to address the balance of vascular benefits and diabetes hazard of statin use...
  6. pmc Cardiovascular inflammation in healthy women: multilevel associations with state-level prosperity, productivity and income inequality
    CHERYL R CLARK
    Division of General Medicine and Primary Care, Brigham and Women s Faulkner Hospitalist Program, Harvard Medical School, Boston, Massachusetts, USA
    BMC Public Health 12:211. 2012
    ....
  7. doi request reprint Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, MA 02215, USA
    Clin Chem 58:877-86. 2012
    ..Whether measures of Lp-PLA(2) mass or activity continue to predict risk after LDL-C reduction by statin therapy is uncertain...
  8. pmc An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation
    Christopher S Coffey
    Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL 35294 0022, USA
    BMC Bioinformatics 5:49. 2004
    ..One advantage of the MDR method is that it provides an internal prediction error for validation. We summarize our use of this internal prediction error for model validation...
  9. ncbi request reprint Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    J Am Coll Cardiol 45:1644-8. 2005
    ..The aim of this research was to compare relative efficacy of different statin regimens in achieving the dual goals of low-density lipoprotein cholesterol (LDL-C) and C-reactive protein (CRP) reduction...
  10. ncbi request reprint Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women
    Paul M Ridker
    Donald W Reynolds Center for Cardiovascular Research, LeDucq Center for Molecular and Genetic Epidemiology, Brigham and Women s Hospital, Boston, MA 02215, USA
    JAMA 294:326-33. 2005
    ....
  11. pmc C-reactive protein, inflammation, and cardiovascular disease: clinical update
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Preventive Medicine Division, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    Tex Heart Inst J 32:384-6. 2005
  12. doi request reprint Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention
    Paul M Ridker
    Center for Cardiovascular Disease Prevention and the Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Circ Cardiovasc Qual Outcomes 2:616-23. 2009
    ..However, whether the absolute risk reduction among such individuals justifies wide application of statin therapy in primary prevention is a controversial issue with broad policy and public health implications...
  13. ncbi request reprint Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
    Hypertension 48:73-9. 2006
    ..These data raise the hypothesis that angiotensin receptor blockade may have anti-inflammatory effects in addition to blood pressure-lowering effects...
  14. ncbi request reprint Should age and time be eliminated from cardiovascular risk prediction models? Rationale for the creation of a new national risk detection program
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, 900 Commonwealth Ave E, Boston, MA 02215, USA
    Circulation 111:657-8. 2005
  15. ncbi request reprint C-reactive protein levels and outcomes after statin therapy
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 352:20-8. 2005
    ..Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown...
  16. ncbi request reprint Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA
    Am Heart Hosp J 2:4-9. 2004
    ..This article provides a clinically oriented overview of appropriate settings in which to measure hsCRP, how to interpret results, and how interventions to reduce vascular risk can be targeted on the basis of hsCRP findings...
  17. ncbi request reprint Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005
    Paul M Ridker
    Center for Cardiovascular Disease Prevention and the Division of Preventive Medicine, Brigham and Women s Hospital, Boston, Mass 02215, USA
    JAMA 295:2270-4. 2006
    ..Whether this situation has changed over the past 5 years or whether similar effects are present among jointly funded trials is unknown...
  18. ncbi request reprint Established and emerging plasma biomarkers in the prediction of first atherothrombotic events
    Paul M Ridker
    Center for Cardiovascular Disease Prevention and the Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, Mass 02115, USA
    Circulation 109:IV6-19. 2004
  19. ncbi request reprint Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: yes
    P M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Thromb Haemost 2:1034-7. 2004
  20. ncbi request reprint High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, Mass 02215, USA
    Am Heart J 148:S19-26. 2004
    ..Inclusion of hs-CRP measurement in risk screening and use of this information to guide preventive therapy could result in a marked improvement in prevention of cardiovascular morbidity and mortality...
  21. ncbi request reprint Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?
    Paul M Ridker
    Donald W Reynolds Center for Cardiovascular Research, Boston, Mass, USA
    Circulation 109:2818-25. 2004
    ..Toward this end, we believe experts in the fields of epidemiology, prevention, vascular biology, and clinical cardiology should be convened to begin discussing the merits of this proposal...
  22. ncbi request reprint Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores
    Paul M Ridker
    Donald W Reynolds Center for Cardiovascular Research and the Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02215, USA
    Circulation 109:1955-9. 2004
    ..However, the positive predictive value of very low (<0.5 mg/L) and very high levels of hsCRP (>10.0 mg/L) is uncertain...
  23. ncbi request reprint Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score
    Paul M Ridker
    Donald W Reynolds Center for Cardiovascular Research and the Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, MA 02215, USA
    JAMA 297:611-9. 2007
    ..Despite improved understanding of atherothrombosis, cardiovascular prediction algorithms for women have largely relied on traditional risk factors...
  24. ncbi request reprint C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, the Division of Preventive Medicine, Brigham and Women s Hospital, The Harvard Medical School, Boston, Massachusetts 02215, USA
    J Am Coll Cardiol 49:2129-38. 2007
    ..In the meantime, however, this consensus position on hsCRP should be one to which both advocates and critics of the inflammatory hypothesis of atherosclerosis can adhere because it is one that can immediately improve patient care...
  25. ncbi request reprint Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test?
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA
    Clin Chem 54:11-3. 2008
  26. doi request reprint A tale of three labels: translating the JUPITER trial data into regulatory claims
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Clin Trials 8:417-22. 2011
    ....
  27. doi request reprint Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention
    Paul M Ridker
    Center for Cardiovascular Disease Prevention and the Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, 900 Commonwealth Avenue East, Boston, MA 02215, USA
    Circ Cardiovasc Genet 4:312-7. 2011
    ..Hypothesis-generating data raise the possibility that carriers of the kinesin-like protein 6 (KIF6) 719 arginine (Arg) allele preferentially benefit from statin therapy, and, on this basis, a commercial assay for KIF6 has been developed...
  28. doi request reprint Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvas
    Paul M Ridker
    Center for Cardiovascular Disease Prevention and Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Circ Cardiovasc Qual Outcomes 3:447-52. 2010
    ..However, trial data directly addressing whether this recommendation defines a patient population in which statin therapy is effective have not previously been published...
  29. doi request reprint HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Lancet 376:333-9. 2010
    ..We addressed, using the JUPITER trial cohort, whether this association remains when LDL-cholesterol concentrations are reduced to the very low ranges with high-dose statin treatment...
  30. doi request reprint Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Boston, Massachusetts, USA
    Am J Cardiol 106:204-9. 2010
    ..In conclusion, as the absolute risk increased with increasing hs-CRP, the absolute risk reduction associated with rosuvastatin within JUPITER was also greatest among those with the greatest entry hs-CRP levels...
  31. doi request reprint Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Am Coll Cardiol 55:1266-73. 2010
    ..We evaluated the efficacy of statin therapy in primary prevention among individuals with moderate chronic kidney disease (CKD)...
  32. doi request reprint Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    J Thromb Haemost 7:332-9. 2009
    ..If successful, CIRT would both confirm the inflammatory hypothesis of atherothrombosis and open novel approaches to the treatment and prevention of cardiovascular disorders...
  33. ncbi request reprint Moving toward new statin guidelines in a post-JUPITER world: principles to consider
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, MA 02215, USA
    Curr Atheroscler Rep 11:249-56. 2009
    ..Although lifestyle interventions remain critical, the screening and treatment strategy tested in JUPITER is likely to impact on new guidelines for cardiovascular disease prevention...
  34. doi request reprint Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 359:2195-207. 2008
    ....
  35. pmc C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men
    Paul M Ridker
    Donald W Reynolds Center for Cardiovascular Research, Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Circulation 118:2243-51, 4p following 2251. 2008
    ....
  36. pmc Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am J Hum Genet 82:1185-92. 2008
    ....
  37. ncbi request reprint Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity
    Paul M Ridker
    Harvard Medical School, Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    Nutr Rev 65:S253-9. 2007
    ..Several novel methods to reduce CRP have been proposed, including direct inhibitors as well as antisense technologies...
  38. ncbi request reprint Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american women
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, MA, USA
    Clin Chem 54:249-55. 2008
    ..Thus, with continued follow-up of the WHS, the WGHS provides a unique scientific resource-a full-cohort, prospective, genome-wide association study among initially healthy American women...
  39. ncbi request reprint Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein
    Paul M Ridker
    JUPITER Coordinating Center, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 100:1659-64. 2007
    ..In conclusion, as 20 mg of rosuvastatin can reduce LDL cholesterol by up to 50%, JUPITER will also provide crucial safety data for several thousand patients who should achieve LDL cholesterol levels<50 mg/dl on a long-term basis...
  40. doi request reprint Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am Heart J 162:597-605. 2011
    ..Yet, it remains unknown whether direct inhibition of inflammation will reduce cardiovascular event rates...
  41. ncbi request reprint Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
    Circulation 108:2292-7. 2003
  42. ncbi request reprint Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease
    P M Ridker
    Brigham and Women s Hospital, 900 Commonwealth Ave E, Boston, MA 02215, USA
    JAMA 285:2481-5. 2001
    ..Several novel risk factors for atherosclerosis have recently been proposed, but few comparative data exist to guide clinical use of these emerging biomarkers...
  43. ncbi request reprint A prospective study of Helicobacter pylori seropositivity and the risk for future myocardial infarction among socioeconomically similar U.S. men
    P M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA
    Ann Intern Med 135:184-8. 2001
    ..The role of Helicobacter pylori as a determinant of cardiovascular disease is controversial...
  44. ncbi request reprint C-reactive protein and risk of cardiovascular disease: evidence and clinical application
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA
    Curr Atheroscler Rep 5:341-9. 2003
  45. ncbi request reprint Clinical application of C-reactive protein for cardiovascular disease detection and prevention
    Paul M Ridker
    Center for Cardiovascular Disease Prevention and the Division of Cardiology, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02215, USA
    Circulation 107:363-9. 2003
  46. ncbi request reprint Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02215, USA
    Circulation 105:1776-9. 2002
    ..Elevated homocysteine levels are associated with increased coronary risk, and it has been suggested that homocysteine screening may provide a method to identify high-risk patients for aggressive primary prevention...
  47. ncbi request reprint C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, Mass 02215, USA
    Circulation 107:391-7. 2003
    ..All of these attributes, however, are associated with increased levels of C-reactive protein (CRP)...
  48. ncbi request reprint Connecting the role of C-reactive protein and statins in cardiovascular disease
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cardiol 26:III39-44. 2003
    ..Confirmation of these preliminary findings, if incorporated into evidence-based guidelines, may profoundly change the approach to diagnosis and treatment of CVD...
  49. ncbi request reprint Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism
    Paul M Ridker
    Center for Cardiovascular Disease Prevention and the Division of Preventive Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston 02215, USA
    N Engl J Med 348:1425-34. 2003
    ..0 and 3.0. However, for long-term management, no therapeutic agent has shown an acceptable benefit-to-risk ratio...
  50. ncbi request reprint Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Ave East, Boston, Mass 02215, USA
    Arterioscler Thromb Vasc Biol 23:859-63. 2003
    ..Because diabetes and atherothrombosis share common antecedents, we sought evidence that this polymorphism might also be associated with reduced risk of myocardial infarction...
  51. ncbi request reprint Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
    P M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 344:1959-65. 2001
    ..We hypothesized that statins might prevent coronary events in persons with elevated C-reactive protein levels who did not have overt hyperlipidemia...
  52. ncbi request reprint Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events
    Paul M Ridker
    Center for Cardiovascular Disease Prevention and the Division of Preventive Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston 02215, USA
    N Engl J Med 347:1557-65. 2002
    ..Both C-reactive protein and low-density lipoprotein (LDL) cholesterol levels are elevated in persons at risk for cardiovascular events. However, population-based data directly comparing these two biologic markers are not available...
  53. ncbi request reprint High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA
    Am J Cardiol 92:17K-22K. 2003
    ....
  54. ncbi request reprint Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
    P M Ridker
    Center for Cardiovascular Disease Prevention and the Divisions of Preventive Medicine, Cardiovascular Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 101:1767-72. 2000
    ..Interleukin-6 (IL-6) plays a central role in inflammation and tissue injury. However, epidemiological data evaluating the role of IL-6 in atherogenesis are sparse...
  55. ncbi request reprint Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Ave East, Boston, Mass 02215, USA
    Circulation 108:e81-5. 2003
  56. ncbi request reprint High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease
    P M Ridker
    Center for Cardiovascular Disease Prevention, Divisions of Cardiovascular Diseases and Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02214, USA
    Circulation 103:1813-8. 2001
    ....
  57. ncbi request reprint Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
    P M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 103:1191-3. 2001
    ..However, the generalizability, speed of onset, and dose-response characteristics of this effect are uncertain...
  58. ncbi request reprint Soluble P-selectin and the risk of future cardiovascular events
    P M Ridker
    Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Circulation 103:491-5. 2001
    ..However, little clinical data are available evaluating the role of soluble P-selectin in determining vascular risk...
  59. ncbi request reprint C-reactive protein is independently associated with fasting insulin in nondiabetic women
    Aruna D Pradhan
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, 900 Commonwealth Ave E, Boston, Mass 02215 1204, USA
    Arterioscler Thromb Vasc Biol 23:650-5. 2003
    ..Insulin resistance is associated with chronic subclinical inflammation, and both conditions are linked with increased risk for type 2 diabetes mellitus and atherothrombotic cardiovascular disease...
  60. ncbi request reprint A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men
    Simin Liu
    Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 900 Commonwealth Avenue East, Boston, MA 02215, USA
    Atherosclerosis 166:323-9. 2003
    ..Apolipoprotein E (apoE) plays an important role in lipid metabolism. Three common alleles in the APOE gene, E2/E3/E4, have been associated with lipoprotein disorders but their effects on myocardial infarction (MI) risk remain uncertain...
  61. ncbi request reprint Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: a nested case-control study
    Robert Y L Zee
    Laboratory of Genetic Epidemiology, Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, 900 Commonwealth Avenue East, Boston, MA 02215, USA
    Atherosclerosis 187:332-5. 2006
    ..An exonic polymorphism (Y402H) in the complement factor H (CFH) gene, which locates within the binding sites for heparin and C-reactive protein, has recently been described and hypothesized to play an important role in atherothrombosis...
  62. ncbi request reprint Prospective evaluation of the alcohol dehydrogenase gamma1/gamma2 gene polymorphism and risk of stroke
    Robert Y L Zee
    Center for Cardiovascular Disease Prevention and the Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Stroke 35:e39-42. 2004
    ..Genetic polymorphism of the alcohol dehydrogenase type 3 gene (ADH1C) has recently been associated with reduced risk of myocardial infarction. However, data on risk of stroke are not available...
  63. ncbi request reprint Sex hormone-binding globulin and serum testosterone are inversely associated with C-reactive protein levels in postmenopausal women at high risk for cardiovascular disease
    Hylton V Joffe
    Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women s Hospital, 221 Longwood Ave, Boston, MA 02215, USA
    Ann Epidemiol 16:105-12. 2006
    ..We hypothesized that high androgens, low estradiol, and low sex hormone-binding globulin (SHBG) would be associated with high CRP in postmenopausal women...
  64. ncbi request reprint Polymorphisms in the advanced glycosylation end product-specific receptor gene and risk of incident myocardial infarction or ischemic stroke
    Robert Y L Zee
    Center for Cardiovascular Disease Prevention, The Donald W Reynolds Center for Cardiovascular Research, The Leducq Center for Molecular and Genetic Epidemiology, Boston, Mass, USA
    Stroke 37:1686-90. 2006
    ..However, to date, no genetic-epidemiological data are available on risk of atherothrombotic events among nondiabetic populations...
  65. doi request reprint Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22
    Kausik K Ray
    TIMI Study Group, Cardiovascular Division and the Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 29:424-30. 2009
    ....
  66. ncbi request reprint High prevalence of metabolic syndrome among young women with nonfatal myocardial infarction
    Lynn L Amowitz
    Division of General Medicine and Women s Health, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Womens Health (Larchmt) 13:165-75; discussion 175. 2004
    ..The aim of this study was to determine if the metabolic syndrome (MetS) or other risk factors might be common among young women with nonfatal myocardial infarction (MI)...
  67. pmc Genome-wide association study identifies variants at the IL18-BCO2 locus associated with interleukin-18 levels
    Meian He
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    Arterioscler Thromb Vasc Biol 30:885-90. 2010
    ..We sought to identify the common genetic variants associated with IL-18 levels...
  68. pmc Association of 77 polymorphisms in 52 candidate genes with blood pressure progression and incident hypertension: the Women's Genome Health Study
    David Conen
    Department of Medicine, Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Hypertens 27:476-83. 2009
    ..The aim of the present study was to assess the association of 77 previously characterized gene variants in 52 candidate genes from various biological pathways with blood pressure (BP) progression and incident hypertension...
  69. pmc A randomized trial of rosuvastatin in the prevention of venous thromboembolism
    Robert J Glynn
    Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 360:1851-61. 2009
    ..Observational studies have yielded variable estimates of the effect of statin therapy on the risk of venous thromboembolism, and evidence from randomized trials is lacking...
  70. ncbi request reprint A prospective evaluation of the heat shock protein 70 gene polymorphisms and the risk of stroke
    Robert Y L Zee
    Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Thromb Haemost 87:622-5. 2002
    ..In this large, prospective study, genetic polymorphisms in the HSP70 genes were not associated with risks of future stroke. Screening for these polymorphisms is unlikely to be a useful tool for risk assessment...
  71. ncbi request reprint Risk factors for progression of peripheral arterial disease in large and small vessels
    Victor Aboyans
    Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA 92093 0607, USA
    Circulation 113:2623-9. 2006
    ..Using noninvasive tests, we assessed the role of traditional and novel risk factors on PAD progression. We hypothesized that the risk factors for large-vessel PAD (LV-PAD) progression might differ from small-vessel PAD (SV-PAD)...
  72. doi request reprint Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
    Paul M Ridker
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Lancet 373:1175-82. 2009
    ..8 mmol/L (<70 mg/dL). However, the benefit of lowering both LDL cholesterol and hsCRP after the start of statin therapy is controversial. We prospectively tested this hypothesis...
  73. ncbi request reprint Interaction between inflammation-related gene polymorphisms and cigarette smoking on the risk of myocardial infarction in the Physician's Health Study
    Sarah A Rosner
    Department of Epidemiology, Harvard School of Public Health Kresge 911, 677 Huntington Avenue, Boston, MA 02115, USA
    Hum Genet 118:287-94. 2005
    ..However, these results should be interpreted with caution due to the potential for false positive results that can arise from analyses with multiple comparisons...
  74. ncbi request reprint Polymorphisms of the phosphodiesterase 4D, cAMP-specific (PDE4D) gene and risk of ischemic stroke: a prospective, nested case-control evaluation
    Robert Y L Zee
    Laboratory of Genetic and Molecular Epidemiology, Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, 900 Commonwealth Avenue East, Boston, Massachusetts 02215, USA
    Stroke 37:2012-7. 2006
    ..Case-control studies in other populations have yielded mixed evidence for association. A recent analysis in a prospective, non-Icelandic study found an association with stroke after stratification by hypertension...
  75. ncbi request reprint Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men
    Aruna D Pradhan
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital and Harvard Medical School, Boston, Mass 02115 1204, USA
    Circulation 106:820-5. 2002
    ..It is not certain, however, whether similar relationships exist for the development of early systemic atherosclerosis...
  76. ncbi request reprint Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study
    Robert J Glynn
    Division of Preventive Medicine, Brigham and Women s Hospital, 900 Commonwealth Ave E, Boston, MA 02215 1204, USA
    Circulation 116:1497-503. 2007
    ..Supplementation with vitamin E may antagonize vitamin K in healthy adults, but it is unclear whether intake of vitamin E decreases the risk of venous thromboembolism (VTE)...
  77. doi request reprint Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study
    Robert J Glynn
    Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Clin Chem 55:305-12. 2009
    ..Although studies of specific populations have suggested that hsCRP is a reliable longitudinal marker, it is unclear how strongly hsCRP tracks in individuals after a single increased concentration...
  78. ncbi request reprint Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women
    Simin Liu
    Center of Cardiovascular Prevention, the Division of Preventive Medicine, Harvard Medical School, Boston 02215, USA
    Am J Clin Nutr 75:492-8. 2002
    ..Recent prospective data suggest that intake of rapidly digested and absorbed carbohydrates with a high dietary glycemic load is associated with an increased risk of ischemic heart disease...
  79. pmc Low sex hormone-binding globulin is associated with the metabolic syndrome in postmenopausal women
    Melissa E Weinberg
    Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
    Metabolism 55:1473-80. 2006
    ..7 kg/m2. An androgenic hormone profile is associated with both the individual components of the metabolic syndrome and clustering of metabolic abnormalities in postmenopausal women...
  80. ncbi request reprint A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women
    Paul M Ridker
    Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, USA
    N Engl J Med 352:1293-304. 2005
    ..Randomized trials have shown that low-dose aspirin decreases the risk of a first myocardial infarction in men, with little effect on the risk of ischemic stroke. There are few similar data in women...
  81. ncbi request reprint Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis
    Robert Y L Zee
    Division of Preventive Medicine, The Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medical School, 900 Commonwealth Avenue East, Boston, MA 02215 1204, USA
    Atherosclerosis 162:217-9. 2002
    ..These data suggest that genetic and environmental determinants each importantly contribute to the vascular risk associated with inflammation...
  82. ncbi request reprint Magnesium intake, C-reactive protein, and the prevalence of metabolic syndrome in middle-aged and older U.S. women
    Yiqing Song
    Division of Preventive Medicine, Brigham and Women s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA
    Diabetes Care 28:1438-44. 2005
    ..The aim of this study was to examine whether and to what extent magnesium intake is related to systemic inflammation and the metabolic syndrome...
  83. ncbi request reprint The effect of including C-reactive protein in cardiovascular risk prediction models for women
    Nancy R Cook
    Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA
    Ann Intern Med 145:21-9. 2006
    ..While high-sensitivity C-reactive protein (hsCRP) is an independent predictor of cardiovascular risk, global risk prediction models incorporating hsCRP have not been developed for clinical use...
  84. ncbi request reprint Purinergic receptor P2Y, G-protein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolism
    Robert Y L Zee
    Laboratory of Genetic and Molecular Epidemiology, Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Harvard Medial School, 900 CommonwealthAvenue East, Boston, MA 02215, USA
    Atherosclerosis 197:694-9. 2008
    ..The present investigation provides evidence for an association of the P2RY12 haplotype H2 with lower risk of DVT/PE; however these findings require replication in other well-designed studies...
  85. ncbi request reprint Tryptophanyl-tRNA synthetase gene polymorphisms and risk of incident myocardial infarction
    Robert Y L Zee
    Center for Cardiovascular Disease Prevention, The LeDucq Center for Cardiovascular Prevention, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Atherosclerosis 181:137-41. 2005
    ..In conclusion, we found no evidence for an association between the common polymorphisms or haplotypes of the tryptophanyl-tRNA synthetase gene tested and risk of myocardial infarction...
  86. ncbi request reprint Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial
    Kausik K Ray
    Brigham and Women s Hospital Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 46:1417-24. 2005
    ..This study sought to evaluate what set of factors correlate with higher or lower C-reactive protein (CRP) levels in patients receiving standard and intensive statin therapy...
  87. ncbi request reprint A prospective evaluation of the CD14 and CD18 gene polymorphisms and risk of stroke
    Robert Y L Zee
    Center for Cardiovascular Disease Prevention, the Division of Preventive Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02215, USA
    Stroke 33:892-5. 2002
    ....
  88. ncbi request reprint Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum
    Paul M Ridker
    Circulation 105:2583-5. 2002
  89. ncbi request reprint Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study
    Robert D Langer
    Department of Family and Preventive Medicine, University of California, San Diego, 9500 Gilman Drive, MC 0978, La Jolla, CA 92093 0978, USA
    Thromb Haemost 93:1108-16. 2005
    ..Some associations differed between women with and without incident CHD, especially for EP, where inflammatory and thrombotic markers were higher in cases. These associations remain speculative pending confirmation in randomized trials...
  90. pmc Association of renin-angiotensin and endothelial nitric oxide synthase gene polymorphisms with blood pressure progression and incident hypertension: prospective cohort study
    David Conen
    Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, USA
    J Hypertens 26:1780-6. 2008
    ..The aim of the present study was to assess the relationship of six previously characterized gene variants in the renin-angiotensin system and the NOS3 gene with blood pressure progression and incident hypertension...
  91. pmc Circulating levels of endothelial adhesion molecules and risk of diabetes in an ethnically diverse cohort of women
    Yiqing Song
    Division of Preventive Medicine, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Diabetes 56:1898-904. 2007
    ..S. postmenopausal women, implicating an etiological role of endothelial dysfunction in the pathogenesis of type 2 diabetes...
  92. ncbi request reprint Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women
    Gavin J Blake
    Center for Cardiovascular Disease Prevention, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02215, USA
    Circulation 106:1930-7. 2002
    ..Nuclear magnetic resonance (NMR) offers an alternative, spectroscopic means of quantifying LDL and of measuring LDL particle size...
  93. ncbi request reprint Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Samia Mora
    Center for Cardiovascular Disease Prevention and Division of Cardiovascular Disease, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA
    Am J Cardiol 97:33A-41A. 2006
    ..Ongoing work will determine whether hs-CRP reduction, independent of LDL cholesterol reduction, results in a net clinical benefit...
  94. pmc Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis
    Daniel I Chasman
    Donald W Reynolds Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital, Boston, Massachusetts, United States of America
    PLoS Genet 5:e1000730. 2009
    ....
  95. ncbi request reprint Association between inflammatory markers, hemostatic, and lipid factors in postinfarction patients
    Tareq S Harb
    Cardiology Unit, Department of Medicine, University of Rochester Medical Center, New York 14642, USA
    Am J Cardiol 91:1120-3. 2003
  96. ncbi request reprint Insulin, proinsulin, proinsulin:insulin ratio, and the risk of developing type 2 diabetes mellitus in women
    Aruna D Pradhan
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA
    Am J Med 114:438-44. 2003
    ..To assess the associations among baseline levels of fasting insulin and proinsulin, proinsulin:insulin ratio, and the development of type 2 diabetes mellitus in apparently healthy middle-aged women...
  97. pmc High-sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular degeneration in women
    Debra A Schaumberg
    Division of Preventive Medicine, 900 Commonwealth Ave E, Boston, MA 02215, USA
    Arch Ophthalmol 125:300-5. 2007
    ..To investigate whether high-sensitivity C-reactive protein (hsCRP) and other biomarkers of inflammation predict age-related macular degeneration (AMD)...
  98. ncbi request reprint Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study
    Aruna D Pradhan
    Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215 1204, USA
    JAMA 288:980-7. 2002
    ..Several inflammatory biomarkers, including CRP, are associated with increased cardiovascular risk. However, whether the effect of HRT on CRP represents a clinical hazard is unknown...
  99. ncbi request reprint C-reactive protein gene variation and type 2 diabetes mellitus: a case-control study
    Robert Y L Zee
    Center for Cardiovascular Disease Prevention, Brigham and Women s Hospital and Harvard Medical School, 900 Commonwealth Avenue East, Boston, MA 02215, USA
    Atherosclerosis 197:931-6. 2008
    ..C-reactive protein (CRP) gene variation, in particular an rs2794521 variant was recently associated with type 2 diabetes mellitus (T2DM) in Pima Indians...

Research Grants11

  1. Training Program in the Epidemiology of CVD
    Paul Ridker; Fiscal Year: 2007
    ..end of abstract) ..
  2. THROMBOTIC, INFLAMMATORY & GENE MARKERS OF CVD IN WOMEN
    Paul Ridker; Fiscal Year: 2002
    ....
  3. SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS
    Paul Ridker; Fiscal Year: 2002
    ....
  4. THROMBOTIC, INFLAMMATORY & GENE MARKERS OF CVD IN WOMEN
    Paul Ridker; Fiscal Year: 2001
    ....
  5. SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS
    Paul Ridker; Fiscal Year: 2001
    ....
  6. THROMBOTIC, INFLAMMATORY & GENE MARKERS OF CVD IN WOMEN
    Paul Ridker; Fiscal Year: 2000
    ....
  7. SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS
    Paul Ridker; Fiscal Year: 2000
    ....
  8. SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS
    Paul Ridker; Fiscal Year: 1999
    ....
  9. THROMBOTIC, INFLAMMATORY & GENE MARKERS OF CVD IN WOMEN
    Paul Ridker; Fiscal Year: 1999
    ....